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ABSTRACT 
Purpose The third most frequently diagnosed cancer in Europe in 2018 was lung cancer; it is also the leading cause of can-
cer death in Europe. We studied patient and tumor characteristics, and patterns of healthcare provision explaining regional 
variability in lung cancer survival in southern Spain.
Methods A population-based cohort study included all 1196 incident first invasive primary lung cancer (C33–C34 accord-
ing to ICD-10) cases diagnosed between 2010 and 2011 with follow-up until April 2015. Data were drawn from local 
population-based cancer registries and patients’ hospital medical records from all public and private hospitals from two 
regions in southern Spain.
Results There was evidence of regional differences in lung cancer late diagnosis (58% stage IV in Granada vs. 65% in Huelva, 
p value < 0.001). Among patients with stage I, only 67% received surgery compared with 0.6% of patients with stage IV. 
Patients treated with a combination of radiotherapy, chemotherapy, and surgery had a 2-year mortality risk reduction of 94% 
compared with patients who did not receive any treatment (excess mortality risk 0.06; 95% CI 0.02–0.16). Geographical 
differences in survival were observed between the two regions: 35% vs. 26% at 1-year since diagnosis.
Conclusions The observed geographic differences in survival between regions are due in part to the late cancer diagnosis 
which determines the use of less effective therapeutic options. Results from our study justify the need for promoting lung 
cancer early detection strategies and the harmonization of the best practice in lung cancer management and treatment.
Keywords Lung cancer · Population-based cancer epidemiology · Hospital medical records · Survival analysis · Excess 
risk · Cancer treatment
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Introduction
Lung cancer was the third most frequently diagnosed cancer 
in Europe in 2018 with 364,601 new cases [1]. In Spain, it is 
estimated that 28,347 new lung cancer cases were diagnosed 
in 2015. Lung cancer is the third most frequently diagnosed 
cancer in men after prostate and colorectal cancer; and the 
fourth in females after breast, colorectal, and endometrial 
cancer [2], excluding non-melanoma skin cancer. Moreover, 
lung cancer was the leading cause of cancer death among 
males in 2012 worldwide [3] with 1,590,000 deaths of lung 
cancer, accounting for 87% of the mortality from cancer and 
making it the leading cause of cancer death in the world [4].
Despite improvements in lung cancer biology and the 
increased diagnostic and therapeutic effort in recent decades, 
lung cancer still has one of the world’s lowest survival [5]. 
The European mean age-standardized 5-year relative sur-
vival for male lung cancer patients diagnosed in 2000–2007 
was 12.0% and 15.9% for female patients [6]. Lung cancer 
survival in Spain had a poor prognosis, with a 5-year relative 
survival of 10.6% (95% CI 10.1–11.2) [7].
Patient and tumor characteristics are important drivers of 
lung cancer survival. For instance, smoking behavior varies 
significantly between individuals and populations reflecting 
geographical and temporal variability in lung cancer inci-
dence [8]. Lung cancer survival among smokers is lower 
than that of non-smokers, but the effect of tobacco on lung 
cancer survival could be mediated by comorbidity associated 
with smoke [9, 10]. Furthermore, stage, age at diagnosis, 
and cancer treatment are the most important determinants 
of lung cancer survival [9]. Current evidence suggests the 
importance of an early diagnosis to allow a better lung can-
cer prognosis [6, 11, 12]. However, it is still difficult to make 
an early diagnosis of lung cancer [13, 14]. Furthermore, dif-
ferences in patterns of healthcare may explain regional vari-
ability in lung cancer survival.
Recently, regional variability in lung cancer survival has 
been found in Spain [15]. We hypothesized that the regional 
variability in lung cancer survival could be characterized by 
patient, tumor, and healthcare provision determinants [16]. 
Characterizing factors associated with regional differences 
in lung cancer survival is extremely important for public 
health professionals and policymakers as it can help them to 
allocate resources and develop strategies to reduce survival 
inequalities. We studied the distribution and frequency 
of patient, tumor, and healthcare provision factors, their 
regional variability, and their association with lung cancer 
survival in southern Spain.
Methods: study design
We develop a population-based cohort study including 1196 
incident lung cancer cases from two population-based can-
cer registries in southern Spain (Huelva and Granada) fol-
lowing international standard procedures and coding rules 
(http://www.hrstu dies.eu/). Both cancer registries follow the 
international recommendations by the IARC (International 
Agency for Research on Cancer) and the ENCR (European 
Network of Cancer Registries) from the beginning of their 
activity (Granada from 1985 and Huelva from 2007). The 
cancer registry from Huelva is more recent than Granada. 
However, it has consolidated data of all anatomical sites 
since 2007 and has published their incidence results else-
where [17].
Cases were diagnosed with a first invasive primary lung 
cancer [C33–C34 according to International Classification 
of Diseases for Oncology, 3rd edition, (ICD-O-3)] between 
2010 and 2011 with follow-up until April 2015. Cancer reg-
istry data related to patients’ sociodemographic and basic 
tumor characteristics were enhanced with information from 
hospital medical records including cancer diagnosis and 
treatment.
Variables included in the study
We included the date of cancer diagnosis from cancer reg-
istration data and patients’ date of death at the end of fol-
low-up extracted from the National Death Index. The vital 
status “alive” was then validated with the information from 
patients’ hospital medical records. In addition to basic soci-
odemographic patient data, the date of diagnosis and the 
vital status, we characterized the information obtained from 
the medical records as patient, tumor, and healthcare provi-
sion factors.
Patient’s characteristics
We included age, gender, smoking status, and comorbidities 
including 19 diseases. Age at diagnosis was categorized into 
five age groups: 15–44, 45–54, 55–64, 65–74 and ≥ 75 years. 
Smoking status was categorized as the current, past, and 
never smoker. Comorbidities were included using the Charl-
son comorbidity index (CCI) and coded according to the 
number of comorbidity conditions: no comorbidity (0–1 
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points), low comorbidity (2 points), high comorbidity (> 2 
points), and unknown [18, 19].
Tumor factors
We included the presence of a previous lung disease, tumor 
topography, morphology, laterality, and stage at diagnosis. 
The final stage variable was defined as the combination of 
clinical and pathological TNM and categorized into five 
groups based on the 7th edition of the TNM manual: stage 
I–IV, and unknown. Topography and morphology (defined 
later) were coded according to the International Classifica-
tion of Diseases for Oncology, 3rd edition (ICD-O-3).
Healthcare provision factors
We included diagnosis type and treatment information from 
medical records. The method of diagnosis was categorized 
as clinical/instrumental only, cytological, or histological 
(including histological diagnosis of metastasis). The clinical 
category included chest X-ray, spiral computed tomography 
(CT), positron emission tomography (PET), magnetic reso-
nance imaging (MRI), bronchoscopy, endobronchial ultra-
sound-guided bronchoscopy (EBUS), and mediastinoscopy. 
If the diagnosis was based on a cytological or a histological 
evaluation, the disease was considered microscopically veri-
fied and was further classified by morphology: adenocar-
cinoma (ADC), squamous cells carcinoma (SqCC), small 
cells carcinoma (SmCC), large cells carcinoma (LCC), and 
other types. Both microscopically verified and unverified 
lung cancer cases were included. First treatment informa-
tion was classified into four different categories: surgery, 
chemotherapy, radiotherapy, targeted treatment, and their 
combination. We also included the time to first treatment 
as the time elapsed between the date of diagnosis and the 
date of the first treatment. Palliative care was defined as the 
treatment administered without curative intent and patients 
who did not receive surgery, chemotherapy, radiotherapy, 
targeted treatment, and their combination were classified as 
untreated.
Statistical analysis
To describe regional variability related to the patient’s 
tumor, diagnostic procedures, and treatment characteristics, 
we used counts and proportions. To assess the strength of 
the statistical differences between regions, we used the Chi-
square test and the Fisher’s exact test when applicable. To 
describe the time to the first treatment, we used the median 
and the interquartile range (IQR). We used the region of 
analysis as a binary dependent variable with the province of 
Huelva as the reference to study regional variability in lung 
cancer treatment using logistic regression models for each 
of the treatment combinations. Odds of receiving treatment 
vs. non-treatment and each combination of treatment vs. 
any other therapy with 95% confidence intervals (CI) were 
computed. Models were adjusted for age, morphology, and 
stage at diagnosis. Then, to compare differences in the time 
to the first treatment by regions, we used the non-parametric 
Mann–Whitney test.
Finally, to investigate lung cancer survival by regions, we 
estimate 1- and 2-year age-standardized net survival using 
the Pohar Perme estimator [20]. To estimate the net survival, 
we used population regional life tables broken down by sex 
and categories of age [21]. For the standardization of the net 
survival by age, we used the standard cancer patient popula-
tion and 95% CI were derived based on the delta method. 
Finally, we investigated regional variability in excess mortal-
ity due to cancer estimating excess mortality risks (EMR) 
using multivariable generalized linear models with a Poisson 
error structure [22]. We used Stata v. 14 (StataCorp, College 
Station, Texas, USA) for the statistical analysis [23].
Results
Patient and tumor factors
Table 1 shows patient and tumor characteristics from 1196 
incident cases of lung cancer in two southern Spanish prov-
inces. The majority of the cases were men (83%) with a 
similar proportion in both regions. Age at diagnosis was 
significantly higher in Granada than in Huelva. Percentage 
of patients over 75 years old was 38% in Granada and 24% in 
Huelva. The percentage of non-smokers was lower in Huelva 
(10%) than in Granada (15%). For both regions, smoking 
in men was more frequent than in women (47% vs. 39%, 
data not shown); however, in Huelva, there was a greater 
percentage of women who smoke than in Granada (50% vs. 
33%, data not shown). The presence of a previous pulmonary 
disease was more frequent in Huelva than Granada (55% vs. 
37%), but the CCI showed higher comorbidity in Granada. 
Microscopic verification was obtained in 80% of cases with 
a higher proportion in Huelva than Granada (85% vs. 76%). 
Significant differences between the two regions were found 
regarding morphology, i.e., the most frequent histological 
type in Granada was adenocarcinoma (40%) but in Huelva 
it was squamous cell carcinoma (25%). Large cell carcinoma 
was much more frequent in Huelva than Granada (16% vs. 
2%). Huelva showed a higher prevalence of stage IV at diag-
nosis than Granada (65% vs. 58%, p value < 0.001).
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Diagnosis procedures, treatment characteristics, 
and time to the first treatment
Tables 2 and 3 show differences in health care provision 
factors between provinces. All diagnostic tests except CT 
and MRI were applied differentially in the two regions. 
Thoracic imaging and bronchoscopy were more frequently 
used in Huelva, whereas PET, mediastinoscopy, and EBUS 
were more frequently used in Granada (Table 2). Chem-
otherapy or radiotherapy was administered to a greater 
percentage of patients in the province of Huelva, while 
Table 1  Distribution of lung cancer patients according to patient 
characteristics and tumor characteristics by region
ADC adenocarcinoma, SqCC squamous cells carcinoma, SmCC small 
cells carcinoma, LCC large cells carcinoma and other types
a Percentage of missing values on all data
b Morphology
Granada Huelva p value
N % N %
Total 760 (100) 436 (100)
Age at diagnosis (years) < 0.001
 15–44 16 (2.1) 15 (3.4)
 45–54 85 (11.2) 54 (12.4)
 55–64 152 (20.0) 130 (29.8)
 65–74 215 (28.3) 133 (30.5)
 ≥ 75 292 (38.4) 104 (23.9)
Sex 0.759
 Men 631 (83.0) 365 (83.7)
 Women 129 (17.0) 71 (16.3)
Smoking habits 0.005
 Yes, currently 269 (41.9) 205 (51.7)
 Yes, previously 278 (43.3) 151 (38.0)
 No, never 95 (14.8) 41 (10.3)
 Unknowna 118 (15.5) 39 (8.9)
Previous lung disease < 0.001
 No 465 (63.5) 190 (44.9)
 Yes 267 (36.5) 233 (55.1)
 Unknowna 28 (3.7) 13 (3.0)
Charlson index < 0.001
 No comorbidity (0–1 points) 85 (11.6) 98 (23.5)
 Low comorbidity (2 points) 88 (12.0) 46 (11.1)
 High comorbidity (> 2 points) 560 (76.4) 272 (65.4)
 Unknowna 27 (3.6) 20 (4.6)
Morphologyb < 0.001
 ADC 234 (40.4) 86 (23.2)
 SqCC 179 (30.9) 93 (25.1)
 SmCC 105 (18.1) 68 (18.3)
 LCC 13 (2.3) 61 (16.4)
 Other 48 (8.3) 63 (17.0)
 Non-microscopic  verificationa 181 (23.8) 65 (14.9)
Laterality 0.034
 Left 303 (41.8) 175 (40.8)
 Right 415 (57.2) 241 (56.2)
 Bilateral 7 (1.0) 13 (3.0)
 Unknowna 35 (4.6) 7 (1.6)
Stage at diagnosis < 0.001
 I 83 (11.3) 25 (6.1)
 II 34 (4.6) 28 (6.8)
 III 193 (26.2) 90 (22.0)
 IV 427 (57.9) 267 (65.1)
 Unknowna 23 (3.0) 26 (6.0)
Table 2  Distribution of lung cancer patients according to diagnosis 
tests by region
IQR interquartile range
a Percentage of missing values on all data
Granada Huelva p value
N % N %
Basis of diagnosis < 0.001
 DCO 9 (1.2) 0 (0.0)
 Clinical 172 (22.6) 61 (14.0)
 Microscopic 579 (76.2) 375 (86.0)
Thorax imaging < 0.001
 Done 668 (90.1) 423 (98.1)
 Not done 73 (9.9) 8 (1.9)
 Unknowna 19 (2.5) 5 (1.1)
Spiral computed tomography 0.190
 Done 709 (95.9) 414 (97.4)
 Not done 30 (4.1) 11 (2.6)
 Unknowna 21 (2.8) 11 (2.5)
Positron emission tomography < 0.001
 Done 371 (50.6) 134 (32.1)
 Not done 362 (49.4) 283 (67.9)
 Unknowna 27 (3.6) 19 (4.4)
Magnetic resonance imaging 0.128
 Done 88 (12.1) 64 (15.3)
 Not done 639 (87.9) 355 (84.7)
 Unknowna 33 (4.3) 17 (3.9)
Bronchoscopy < 0.001
 Done 483 (64.9) 391 (91.6)
 Not done 261 (35.1) 36 (8.4)
 Unknowna 16 (2.1) 9 (2.1)
Mediastinoscopy 0.007
 Done 79 (10.8) 25 (6.0)
 Not done 653 (89.2) 390 (94.0)
 Unknowna 28 (3.7) 21 (4.8)
Endobronchial ultrasound guided bronchoscopy < 0.001
 Done 302 (40.8) 3 (0.7)
 Not done 439 (59.2) 412 (99.3)
 Unknowna 19 (2.5) 21 (4.8)
Clinical and Translational Oncology 
1 3
surgery or targeted therapy was applied in a similar pro-
portion (Table 3).  
Surgery was only indicated in 15% of all stages patients in 
both regions. For each stage, patients who received surgery 
were 81% with stage I, 55% with stage II, 11% with stage 
III and 2% with stage IV (data not shown). Our study shows 
that treatments containing surgery are performed in a very 
small percentage of patients in stage IV (0.9% radio + sur-
gery, 0.3% chemo + surgery and 0.4% radio + chemo + sur-
gery) (data not shown).
Forty percent of the patients in Granada and 32% in 
Huelva received treatment without curative intent. The first 
treatment with surgery or target treatment had similar per-
centages in both regions. There was a greater tendency in 
Huelva compared to Granada to administer only radiother-
apy (13% vs. 5%), radiotherapy along with chemotherapy 
(24% vs. 16%) or the combination of radiotherapy, chemo-
therapy, and surgery (4% vs. 2%). In contrast, treatment with 
chemotherapy alone (20% vs. 14%) or surgery alone (10% 
vs. 6%) was more common in Granada (Table 3).
We found a greater probability of treatment with only 
radiotherapy in Huelva than in Granada (OR = 2.8; 95% CI 
1.8–4.4), whereas in Granada the probability of performing 
only surgery (OR = 0.5; 95% CI 0.2–1.0) or only chemo-
therapy (OR = 0.5; 95% CI 0.4–0.8) was higher (Table 4).
The time elapsed from diagnosis to the first treat-
ment was higher in Granada (median of 43  days; IQR 
26–82 days) compared to Huelva (39 days; IQR 18–64 days) 
(p value < 0.001). Chemotherapy was the first therapeutic 
option both in Granada (first treatment administered in 35% 
of patients) and in Huelva [although with a lower percentage 
(29%)] followed by radiotherapy (24% in Huelva vs. 10% in 
Granada).
Age‑standardized net survival and excess mortality 
risk
Survival was greater in Granada than in Huelva, in both men 
and women. 1-year net survival was 35% in Granada vs. 26% 
in Huelva, and 2-year net survival was 21% in Granada vs. 
17% in Huelva. Survival in females was higher than males in 
the two regions, with percentages almost twice higher than 
males 2 years after diagnosis. Greater survival in Granada 
was observed in all age groups, although it was more pro-
nounced between 45 and 64 years of age (Table 5). However, 
stratified analysis by cancer stage only showed a higher sur-
vival probability in Granada for patients with cancer stage 
Table 3  Distribution of lung cancer patients according to treatments 
by region
IQR interquartile range
a Percentage of missing values on all data
Granada Huelva p value
N % N %
Surgery 0.949
 Done 110 (14.8) 62 (14.9)
 Not done 635 (85.2) 354 (85.1)
 Unknowna 15 (2.0) 20 (4.6)
Radiotherapy < 0.001
 Done 187 (25.4) 185 (46.6)
 Not done 550 (74.6) 212 (53.4)
 Unknowna 23 (3.0) 39 (8.9)
Chemotherapy 0.020
 Done 307 (41.6) 195 (48.8)
 Not done 431 (58.4) 205 (51.2)
 Unknowna 22 (2.9) 36 (8.3)
Target treatment 0.310
 Done 27 (3.7) 11 (2.5)
 Not done 704 (96.3) 425 (97.5)
 Unknowna 29 (3.8) 0 (0.0)
First treatment administered < 0.001
 Untreated 297 (40.3) 134 (32.0)
 Surgery 97 (13.2) 59 (14.1)
 Radiotherapy 72 (9.8) 98 (23.5)
 Chemotherapy 257 (34.9) 120 (28.8)
 Target treatment 14 (1.9) 6 (1.4)
 Unknowna 23 (3.0) 19 (4.4)
Combination of treatment < 0.001
 Untreated 297 (40.3) 134 (32.0)
 Only chemotherapy 145 (19.7) 57 (13.6)
 Only surgery 73 (9.9) 25 (6.0)
 Only radiotherapy 40 (5.4) 56 (13.4)
 Radio + chemo 120 (16.3) 100 (23.9)
 Radio + surgery 5 (0.7) 4 (0.9)
 Chemo + surgery 18 (2.4) 15 (3.6)
 Radio + chemo + surgery 12 (1.6) 17 (4.0)
 Target treatment 27 (3.7) 11 (2.6)
 Unknowna 23 (3.0) 17 (3.9)
Table 4  Odds ratio (OR) of undergoing treatment in Huelva refer-
enced to Granada adjusted for age at diagnosis, stage, and morphol-
ogy
Treatment OR 95% CI p value
Untreated 0.85 (0.60–1.20) 0.367
Only chemotherapy 0.52 (0.36–0.76) 0.001
Only surgery 0.50 (0.24–1.03) 0.060
Only radiotherapy 2.76 (1.75–4.36) < 0.001
Radio + chemo 1.23 (0.85–1.77) 0.271
Radio + surgery 2.02 (0.51–8.05) 0.318
Chemo + surgery 1.37 (0.60–3.14) 0.462
Radio + chemo + surgery 2.13 (0.90–5.02) 0.084
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IV, while in stages I–III Huelva obtained better indicators 
than Granada 2-year after diagnosis (Table 5).
Multivariable adjustment showed moderate evidence for 
higher excess cancer mortality in Huelva than Granada with 
13% 2-year EMR of death (95% CI 0.97–1.30). All treat-
ment combinations including surgery showed better survival 
than any other treatment combination without surgery. The 
most effective treatment regarding 2-year survival was the 
combination of radiotherapy, chemotherapy, and surgery, 
reducing the risk of death by 94% compared to patients who 
did not receive this combination of treatment (EMR = 0.06; 
95% CI 0.02–0.16). Patients who were treated with a single 
therapeutic option other than surgery had a lower reduction 
in the risk of death compared to other treatments combina-
tions (Table 6).
Discussion
The present population-based study analyzed lung cancer 
net survival in patients diagnosed in two southern Span-
ish regions and showed geographical differences of patient, 
tumor, and healthcare provision determinants associated 
with 1- and 2-year net survival probability (age-stand-
ardized 1-year net survival was 35% in Granada and 26% 
in Huelva). 1-year age-standardized net survival for lung 
cancer in southern Spain is lower than the overall Span-
ish 1-year age-standardized net survival, i.e., 38% (95% CI 
37–38) and the European, 39% (95% CI 38.8–39.2) [15, 
24]. Furthermore, we found that more than 50% of cases 
were diagnosed late (stage IV) and the prevalence of late 
diagnosis was different between the study regions (58% in 
Granada vs. 65% in Huelva).
The prevalence of tobacco smoking and lung disease was 
higher in Huelva than in Granada; patients in Huelva were 
younger and showed lower comorbidity, both which could 
mean a better prognosis concerning survival [25, 26]. How-
ever, although older age is associated with a worse progno-
sis, some studies show tumors in younger patients are more 
aggressive than in older patients, as has been observed in 
the present study. In this regard, Sacher et al. [27] conclude 
that younger age is associated with an increased likelihood 
of harboring a targetable genotype and the survival of young 
patients with that genotype is unexpectedly poor compared 
with other age groups, suggesting more aggressive disease 
biology. On the other hand, in Huelva, a higher number of 
patients were diagnosed in stage IV and a lower percentage 
in stage I, which suggests that the difference in survival is 
due to late diagnosis. In fact, survival in Huelva is superior 
to Granada in all stages except stage IV, which reinforces 
this hypothesis. Also, in Huelva, there was a higher percent-
age of bilateral tumors, which have a worse prognosis and 
are more difficult to approach from the therapeutic point of 
view [28–30].
Women have a lower incidence of lung cancer than men 
as generally they smoke less than men [31]. However, the 
smoking prevalence in Spain has declined in men from 
65% in 1978 to 31% in 2015, but it has increased from 17% 
in 1975 to 25% in 2015 [32]. This new pattern of tobacco 
consumption has important implications for the incidence 
and mortality of lung cancer by sex in Spain. For instance, 
the lung cancer sex-specific incidence rate ratio for men 
Table 5  1 and 2-year net 
survival (NS) and 95% 
confidence interval (CI) by 
region, sex, age, and stage
a Age-standardized net survival
Granada Huelva
1-year NS (95% CI) 2-year NS (95% CI) 1-year NS (95% CI) 2-year NS (95% CI)
Totala 34.7 (31.5–38.0) 20.7 (17.7–23.7) 26.3 (22.9–29.9) 16.5 (13.2–20.0)
Sexa
 Men 31.9 (28.4–35.3) 17.4 (14.5–20.5) 23.8 (20.2–27.7) 14.8 (11.4–18.6)
 Women 50.0 (40.8–58.5) 32.9 (23.5–42.5) 41.3 (29.1–53.1) 29.7 (18.3–42.0)
Age at diagnosis (years)
 15–44 37.5 (17.5–57.6) 23.9 (7.7–45.0) 33.4 (13.7–54.6) 25.0 (7.6–47.5)
 45–54 42.7 (32.8–52.1) 28.9 (20.0–38.4) 33.5 (22.7–44.5) 15.8 (8.0–25.9)
 55–64 44.5 (36.9–51.7) 27.8 (21.0–35.0) 35.0 (27.7–42.3) 21.0 (14.7–28.0)
 65–74 37.2 (31.4–43.1) 20.7 (15.7–26.1) 26.0 (20.0–32.4) 19.0 (13.1–25.7)
 ≥ 75 20.6 (17.1–24.3) 10.8 (7.7–14.4) 15.2 (10.8–20.38) 8.6 (4.4–14.5)
Stage at  diagnosisa
 I 88.8 (78.3–94.4) 75.0 (62.5–83.8) 83.1 (59.4–93.7) 84.2 (59.2–94.5)
 II 71.3 (51.8–84.1) 56.3 (36.3–72.2) 68.7 (46.0–83.4) 60.5 (37.1–77.6)
 III 39.6 (33.2–46.0) 20.2 (14.9–26.0) 45.5 (35.4–55.0) 28.0 (19.1–37.5)
 IV 16.3 (13.9–18.8) 5.4 (3.8–7.4) 11.5 (9.3–14.0) 1.8 (0.9–3.3)
 Unknown 34.3 (13.6–56.5) 24.9 (6.7–49.1) 40.4 (21.7–58.4) 29.2 (12.1–48.9)
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compared with women has decreased importantly from 9.6 
times in the period 1993–1997 to 6.3 in 2003–2007 [33].
Overall we found higher lung cancer survival among 
women compared with men which is in line with research 
in other countries [34]. The mechanisms for these differ-
ences are not yet well understood but differences between 
the sexes such as health-seeking behavior have been pos-
tulated as a possible hypothesis to explain the differences 
[35–38]. For instance, a study in Spain found that women 
have worse perceptions of their health than men, making 
them attend health services more frequently than men [39].
We found remarkable differences related to the provi-
sion of cancer care in both southern regions that might 
explain cancer survival outcomes. All diagnostic tests 
except CT and MRI were applied differentially in the two 
regions. Thoracic imaging and bronchoscopy were more 
frequently used in Huelva, whereas PET, mediastinoscopy, 
and EBUS were more commonly used in Granada. Treat-
ments that include surgery are more effective for the sur-
vival of lung cancer patients, although their use is only 
indicated in tumors in early stages. Besides, in a large 
number of patients, the only therapeutic option is with pal-
liative intent, mainly because they are elderly patients with 
distant metastasis. That is why, to maximize the probabil-
ity of survival, efforts for early detection of lung cancer 
must increase. We observed that the combination of treat-
ments improves survival. Of all combinations, those that 
included surgery had the best results reducing death risk. 
The most effective treatment regarding survival was the 
combination of radiotherapy, chemotherapy, and surgery, 
reducing the risk of death by 94% compared to patients 
who did not receive treatment. Chemotherapy combined 
with surgery and surgery alone was also more effective 
than the other treatments. It is important to emphasize the 
relevance of early cancer detection for lung cancer surgery 
and survival. Nevertheless, surgery is only indicated in 
early stages. However, early lung cancer detection is still 
difficult [40]. In our study, surgery was only indicated in 
15% of patients who were mostly in stage I (81%). Only 
17 of the 1196 cases analyzed (1.4%) were included in a 
clinical trial at the time of the investigation.
A recent improvement of new therapies has had a slight 
influence in lung cancer survival—1-year survival rates have 
modestly increased, particularly among women who have 
a better prognosis and higher survival [41]. Unfortunately, 
the use of these new therapies, in particular, tyrosine kinase 
inhibitors [42, 43], has been scarce during the period of this 
study. It could be due to the slow introduction of some new 
treatments in our community. When analyzing the type of 
treatment, we observed that untreated patients have the high-
est percentages as they represent 40% and 32% in Granada 
and Huelva, respectively. Lung cancer patients, who were in 
poor condition and exhibited severe chronic complications 
Table 6  Excess mortality risks of death, with 95% confidence inter-
vals, according to region, demographics characteristics, tumor charac-
teristics, and treatments
EMR 95% CI p value
Region
 Granada 1 – –
 Huelva 1.13 (0.97–1.30) 0.118
Sex
 Men 1.01 (0.81–1.27) 0.921
 Women 1 – –
Age
 15–54 1.05 (0.80–1.37) 0.726
 55–64 1.01 (0.82–1.26) 0.897
 65–74 1.09 (0.91–1.31) 0.351
 ≥ 75 1 – –
Smoker
 Yes, currently 1.88 (1.44–2.46) < 0.001
 Yes, previously 1.76 (1.35–2.31) < 0.001
 No, never 1 – –
 Unknown 1.26 (0.92–1.73) 0.149
Charlson index
 No comorbidity (0–1 points) 1 – –
 Low comorbidity (2 points) 0.93 (0.70–1.24) 0.612
 High comorbidity (> 2 points) 1.15 (0.93–1.43) 0.203
 Unknown 1.19 (0.73–1.94) 0.479
Stage
 I 1 – –
 II 2.04 (1.07–3.90) 0.030
 III 4.02 (2.37–6.82) < 0.001
 IV 9.10 (5.40–15.32) < 0.001
 Unknown 5.47 (2.85–10.49) < 0.001
Morphology
 ADC 1 – –
 SqCC 1.04 (0.85–1.29) 0.690
 SmCC 1.2 (0.96–1.50) 0.101
 LCC 0.94 (0.69–1.28) 0.698
 Other 0.97 (0.73–1.27) 0.800
Non-microscopic verification 1.32 (1.06–1.65) 0.012
Combination of treatment administered
 Untreated 1 – –
 Only chemotherapy 0.31 (0.25–0.38) < 0.001
 Only surgery 0.18 (0.10–0.30) < 0.001
 Only radiotherapy 0.52 (0.40–0.67) < 0.001
 Radio + chemo 0.24 (0.19–0.30) < 0.001
 Radio + surgery 0.21 (0.09–0.49) < 0.001
 Chemo + surgery 0.13 (0.06–0.26) < 0.001
 Radio + chemo + surgery 0.06 (0.02–0.16) < 0.001
 Target treatment 0.18 (0.12–0.28) < 0.001
 Unknown 0.51 (0.31–0.82) 0.006
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or were in the late stages of the disease, usually receive only 
palliative treatment or no treatment at all.
To the extent of our knowledge, this is the first high-res-
olution study showing regional variability in patient, tumor, 
and healthcare determinants that also highlights a remark-
ably high prevalence of late diagnosis in Spain. However, 
more consistent comparative evidence is needed in terms 
of calendar time and sample size to externally validate the 
relevance of our findings.
In summary, the observed regional differences in lung 
cancer may be due to the late cancer diagnosis, which deter-
mines the use of less effective therapeutic options. Patient, 
tumor, and provision of healthcare determinants could par-
tially explain the observed geographical variability. The 
results of our study justify the need for monitoring adher-
ence to regional guidelines and promoting the harmoniza-
tion of the best practice in lung cancer management and 
treatment.
Acknowledgements Maria Jose Sanchez Perez is supported by the 
Andalusian Department of Health: Research, Development, and Inno-
vation Office project grant PI-0152/2017. Miguel Angel Luque-Fernan-
dez is supported by the Spanish National Institute of Health, Carlos III 
Miguel Servet I Investigator Award (CP17/00206).
Compliance with ethical standards 
Conflict of interest The authors declare that there is no conflict of in-
terest regarding the publication of this article.
Ethical approval This study involves a secondary data analysis from 
existing data and records. The information was recorded by the inves-
tigator in such a manner that subjects could not be identified, directly 
or through identifiers linked to the subjects. The regional ethical review 
board approved the study proposal. Furthermore, data from the partici-
pant cancer registry has data management policies in place allowing 
for the preservation of individual patients’ confidentiality including the 
ethical approvals from local mandatory bodies.
Informed consent For this type of study formal consent is not required 
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. ECIS European Commission. https ://ecis.jrc.ec.europ a.eu/. 
Accessed 01 Mar 2018.
 2. Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas 
D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 
2017;19:799–825.
 3. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. 
Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
 4. WHO. Globocan 2012—Home [Internet]. Globocan 2012. 2012. 
http://globo can.iarc.fr/Defau lt.aspx. Accessed 1 Mar 2018.
 5. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić 
M, et al. Global surveillance of trends in cancer survival 2000–14 
(CONCORD-3): analysis of individual records for 37,513,025 
patients diagnosed with one of 18 cancers from 322 population-
based registries in 71 countries. Lancet. 2018;391:1023–75.
 6. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pieran-
nunzio D, et al. Cancer survival in Europe 1999–2007 by country 
and age: results of EUROCARE-5—a population-based study. 
Lancet Oncol. 2014;15:23–34.
 7. Chirlaque MD, Salmerón D, Galceran J, Ameijide A, Mateos 
A, Torrella A, et al. Cancer survival in adult patients in Spain. 
Results from nine population-based cancer registries. Clin Transl 
Oncol. 2018;20(2):201–11.
 8. Wong MCS, Lao XQ, Ho K-F, Goggins WB, Tse SLA. Incidence 
and mortality of lung cancer: global trends and association with 
socioeconomic status. Sci Rep. 2017;7:14300.
 9. Tammemagi CM, Neslund-Dudas C, Simoff M, Kvale P. Smoking 
and lung cancer survival: the role of comorbidity and treatment. 
Chest. 2004;125:27–37.
 10. Nordquist LT, Simon GR, Cantor A, Alberts WM, Bepler G. 
Improved survival in never-smokers vs current smokers with 
primary adenocarcinoma of the lung. Chest. 2004;126:347–51.
 11. Tan YK, Wee TC, Koh WP, Wang YT, Eng P, Tan WC, et al. 
Survival among Chinese women with lung cancer in Singapore: 
a comparison by stage, histology and smoking status. Lung Can-
cer. 2003;40:237–46.
 12. Fry WA, Phillips JL, Menck HR. Ten-year survey of lung can-
cer treatment and survival in hospitals in the United States: a 
national cancer data base report. Cancer. 1999;86:1867–76.
 13. Alberts WM. Diagnosis and management of lung cancer execu-
tive summary: aCCP evidence-based clinical practice guide-
lines. Chest. 2007;132:1S–19S (2nd edition).
 14. Xie L, Ugnat A-M, Morriss J, Semenciw R, Mao Y. Histology-
related variation in the treatment and survival of patients with 
lung carcinoma in Canada. Lung Cancer. 2003;42:127–39.
 15. Salmerón D, Chirlaque MD, Isabel Izarzugaza M, Sánchez 
MJ, Marcos-Gragera R, Ardanaz E, et al. Lung cancer prog-
nosis in Spain: the role of histology, age and sex. Respir Med. 
2012;106:1301–8.
 16. Woods LM, Rachet B, Coleman MP. Origins of socio-eco-
nomic inequalities in cancer survival: a review. Ann Oncol. 
2006;17:5–19.
 17. Viñas Casasola MJ, Fernández Navarro P, Fajardo Rivas ML, 
Gurucelain Raposo JL, Alguacil Ojeda J. Distribución munici-
pal de la incidencia de los tumores más frecuentes en un área 
de elevada mortalidad por cáncer. Gac Sanit. 2017;31:100–7.
 18. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to 
measure comorbidity: a critical review of available methods. J 
Clin Epidemiol. 2003;56:221–9.
 19. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new 
method of classifying prognostic comorbidity in longitu-
dinal studies: development and validation. J Chronic Dis. 
1987;40:373–83.
 20. Perme MP, Stare J, Esteve J. On estimation in relative survival. 
Biometrics. 2012;68:113–20.
 21. Corazziari I, Quinn M, Capocaccia R. Standard cancer patient 
population for age standardising survival ratios. Eur J Cancer. 
2004;40:2307–16.
 22. Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression 
models for relative survival. Stat Med. 2004;23:51–64.
 23. StataCorp. Stata statistical software: release 12. College Station: 
StataCorp LP; 2011.
 24. Francisci S, Minicozzi P, Pierannunzio D, Ardanaz E, Eberle A, 
Grimsrud TK, et al. Survival patterns in lung and pleural cancer 
Clinical and Translational Oncology 
1 3
in Europe 1999-2007: results from the EUROCARE-5 study. 
Eur J Cancer. 2015;51:2242–53.
 25. Aggarwal C, Langer CJ. Older age, poor performance sta-
tus and major comorbidities: how to treat high-risk patients 
with advanced nonsmall cell lung cancer. Curr Opin Oncol. 
2012;24:130–6.
 26. Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W, 
Batura-Gabryel H. Comorbidities with non-small cell lung cancer: 
is there an interdisciplinary consensus needed to qualify patients 
for surgical treatment? Ann Thorac Med. 2018;13:101–7.
 27. Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. 
Lung cancer diagnosed in the young is associated with enrichment 
for targetable genomic alterations and poor prognosis HHS Public 
Access. JAMA Oncol. 2016;1:313–20.
 28. De Leyn P, Moons J, Vansteenkiste J, Verbeken E, Van Raem-
donck D, Nafteux P, et al. Survival after resection of synchronous 
bilateral lung cancer. Eur J Cardio Thorac Surg. 2008;34:1215–22.
 29. Tsunezuka Y, Matsumoto I, Tamura M, Oda M, Ohta Y, Shimizu 
J, et al. The results of therapy for bilateral multiple primary lung 
cancers: 30 years experience in a single centre. Eur J Surg Oncol. 
2004;30:781–5.
 30. Mun M, Kohno T. Single-stage surgical treatment of syn-
chronous bilateral multiple lung cancers. Ann Thorac Surg. 
2007;83:1146–51.
 31. Gandini S, Botteri E, Iodice S, Boniol M, Lowenfels ABB, Mai-
sonneuve P, et al. Tobacco smoking and cancer: a meta-analysis. 
Int J Cancer. 2008;122:155–64.
 32. Sánchez-Cruz JJ, García LI, Mayoral JM. Encuesta andaluza de 
salud 2015–2016 de Adultos. Sevilla: Consejería de Salud. Junta 
de Andalucía; 2016.
 33. Galceran J, Amejeide A, Carulla M, Mateps A, Quirós JR, Alemán 
A, et al. Estimaciones de la incidencia y la supervivencia del 
cáncer en españa y su situación en europa. Red Española de Reg-
istros de Cáncer. 2014;1–58.
 34. Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in 
women: analysis of the national surveillance, epidemiology, and 
end results database. Chest. 2005;127:768–77.
 35. Moore R, Doherty D, Chamberlain R, Khuri F. Sex differences in 
survival in non-small cell lung cancer patients 1974-1998. Acta 
Oncol. 2004;43:57–64.
 36. Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: 
do tumors behave differently in elderly women? J Clin Oncol. 
2007;25:1705–12.
 37. Micheli A, Ciampichini R, Oberaigner W, Ciccolallo L, de 
Vries E, Izarzugaza I, et al. The advantage of women in can-
cer survival: an analysis of EUROCARE-4 data. Eur J Cancer. 
2009;45:1017–27.
 38. Skuladottir H, Olsen JH. Can reproductive pattern explain better 
survival of women with lung cancer? Acta Oncol. 2006;45:47–53.
 39. Redondo-Sendino A, Guallar-Castillón P, Banegas JR, Rodríguez-
Artalejo F. Gender differences in the utilization of health-care 
services among the older adult population of Spain. BMC Public 
Health. 2006;6:155.
 40. Salomaa E-R, Sallinen S, Hiekkanen H, Liippo K. Delays in the 
diagnosis and treatment of lung cancer. Chest. 2005;128:2282–8.
 41. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, 
Capocaccia R. EUROCARE-4. Survival of cancer patients diag-
nosed in 1995–1999. Results and commentary. Eur J Cancer. 
2009;45:931–91.
 42. Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT, 
Carter BW. Targeted Therapy and Immunotherapy in the Treat-
ment of Non-Small Cell Lung Cancer. Radiol Clin North Am. 
2018;56:485–95.
 43. Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, 
Okuma Y, et al. Smoking History as a predictor of epidermal 
growth factor receptor tyrosine kinase inhibitors in patients with 
non-small cell lung cancer harboring EGFR mutations. Oncology. 
2018;95(2):109–15.
